Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

Rhea-AI Summary

Heat Biologics, Inc. (NASDAQ:HTBX) has announced that CEO Jeff Wolf will present at the Inaugural Emerging Growth Virtual Conference from March 17-19, 2021, hosted by M Vest LLC and Maxim Group LLC. This presentation is accessible to registered participants and will later be available on the company's website. Heat Biologics focuses on developing immune-modulating therapies, including its gp96 platform targeting cancer and infectious diseases. Key projects include HS-110 in Phase 2 trials and a COVID-19 vaccine in preclinical development.

DURHAM, NC / ACCESSWIRE / March 8, 2021 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced that Jeff Wolf, CEO of Heat Biologics, has been invited to present at Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The presentation will be available to all registered participants of the conference (link) on March 17^th - 19^th and will be posted on Heat Biologics' website (link) after March 19^th.

About Heat Biologics, Inc.

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.

Media and Investor Relations Contact

David Waldman
+1 919 289 4017
investorrelations@heatbio.com

SOURCE: Heat Biologics, Inc.

View source version on accesswire.com:
https://www.accesswire.com/633781/Heat-Biologics-to-Participate-at-M-Vest-LLC-and-Maxim-Group-LLC-Inaugural-Emerging-Growth-Virtual-Conference

FAQ

When will Heat Biologics present at the Emerging Growth Virtual Conference?

Heat Biologics will present at the Emerging Growth Virtual Conference from March 17-19, 2021.

Who is the CEO of Heat Biologics?

The CEO of Heat Biologics is Jeff Wolf.

What is the focus of Heat Biologics?

Heat Biologics focuses on developing first-in-class therapies to modulate the immune system.

What are the key products in development by Heat Biologics?

Key products include HS-110, which is in Phase 2 trials, and a COVID-19 vaccine in preclinical development.

Where can I find the presentation after the conference?

The presentation will be available on Heat Biologics' website after March 19, 2021.